Susquehanna International Group
CMMB

Susquehanna International Group’s Chemomab Therapeutics CMMB Stock Holding History

Susquehanna International Group’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.2K Buy
+13,491
New +$23K ﹤0.01% 12852
2024
Q2 		– Sell
-2,869
Closed -$8.94K – 12151
2024
Q1 		$8.94K Buy
+2,869
New +$7.39K ﹤0.01% 11917

Other funds holding CMMB

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
SP
SmartHarvest Portfolios Poulsbo, Washington $240M AUM
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
PIP
Philadelphia Investment Partners Voorhees, New Jersey $147M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Susquehanna International Group's CMMB Position: Q1 2026 in Review

Susquehanna International Group opened a new position in Chemomab Therapeutics (CMMB) in Q1 2026: 13,491 shares worth $21.2K. The stake represents ﹤0.01% of the portfolio and ranks #12852 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in CMMB as recently as Q1 2024.

Susquehanna International Group first reported a position in CMMB in Q1 2024 and has held it in 2 quarters since. 15 funds tracked by Wall St. Rank hold CMMB as of Q1 2026.

  • Susquehanna International Group held 13,491 shares of Chemomab Therapeutics worth $21.2K as of Q1 2026.
  • Chemomab Therapeutics was a new Susquehanna International Group position in Q1 2026.
  • Chemomab Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12852 holding.
  • Susquehanna International Group first reported a position in Chemomab Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • 15 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.